CRNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Crinetics Pharmaceuticals Inc (CRNX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong long-term growth potential, supported by positive analyst sentiment, significant hedge fund buying, and promising product launches. Despite short-term technical weakness, the long-term outlook and catalysts outweigh the negatives.
The MACD is negatively expanding (-0.801), indicating bearish momentum. RSI is neutral at 25.924, and moving averages are converging, suggesting indecision. The stock is trading near its support level (S1: 44.587), with resistance at 48.03. Overall, the technical indicators suggest short-term weakness but potential for a rebound.
Analysts have raised price targets significantly, with targets ranging from $84 to $105, citing strong product launches and pipeline execution.
Hedge funds have increased buying by 448.61% in the last quarter.
The Palsonify launch in Acromegaly has exceeded expectations, with strong early adoption and positive feedback from endocrinologists.
The stock has experienced a -7.41% regular market decline recently, indicating short-term bearish sentiment.
No recent news or congress trading data to provide additional support.
Financials show a net loss of -$130.09M in Q3 2025, though this is an improvement YoY.
In Q3 2025, revenue remained flat YoY at $143,000, while net income improved significantly to -$130.09M (up 69.33% YoY). EPS improved to -1.38 (up 43.75% YoY). Gross margin remains strong at 100%. While the company is not yet profitable, the financials show improving trends.
Analysts are overwhelmingly positive, with multiple firms raising price targets and maintaining Buy or Outperform ratings. The consensus highlights strong product launches, pipeline execution, and potential blockbuster drugs in development.
